A Team Approach to Diagnosing and Managing Fibromyalgia
Daniel Clauw, MD
Professor of Anesthesiology, Medicine (Rheumatology), and Psychiatry
Director, Chronic Pain and Fatigue Research Center
Department of Anesthesiology
University of Michigan Medical School
Ann Arbor, Michigan
Dr. Clauw presents the latest evidence-based approaches for the diagnosis and management of fibromyalgia, focusing on the controversies and challenges involved in proper assessment of this often misunderstood condition. He reviews the latest pharmacologic and nonpharmacologic treatment options and provides practical advice on how to achieve positive patient outcomes.
Method of Participation and Evaluation
To participate in this CME activity, please read the following information and click "Launch Program" at the bottom of this page. Complete the online evaluation at the conclusion of the activity. Please note: To view this program you need a computer with an Internet browser and audio and video capabilities.
Up to 1.0 AMA PRA Category 1 Credit™
This CME activity is designed for neurologists, rheumatologists, psychiatrists, primary care physicians, OB/GYNs, nurse practitioners, and nurses who treat patients with fibromyalgia.
This activity is provided by the Foundation for Improving Patient Outcomes.
After taking part in this CME activity, learners should be better able to:
- Summarize current evidence supporting the pathophysiology of fibromyalgia and addressing the controversy questioning the status of fibromyalgia as a distinct disorder
- Identify the characteristic symptoms of fibromyalgia and commonly associated medical and psychiatric comorbidities
- Evaluate the efficacy and safety of available and investigational nonpharmacologic and pharmacologic options for the management of fibromyalgia
- Apply best practice strategies for the diagnosis, treatment, and long-term management of patients with fibromyalgia
- Implement a multidisciplinary team approach to optimize the management of patients with fibromyalgia
Daniel Clauw, MD
Daniel Clauw, MD, has served as a consultant to Cypress Biosciences, Inc., Forest Laboratories, Inc., Jazz Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Pierre Fabre Pharmaceuticals USA, Pfizer Inc, and UCB Pharma, Inc.; and has received research support from Forest Laboratories, Inc., and Merck & Co., Inc.
The Foundation for Improving Patient Outcomes staff and the independent peer reviewer report no financial relationship with commercial interests.
CME Credit Designations
ACCME The Foundation for Improving Patient Outcomes (FFIPO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA FFIPO designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of the activity.
AOA This activity is eligible for up to 1.0 hour of credit in Category 2-A of the American Osteopathic Association.